摘要
目的:探究SIL-TAL1融合基因阳性的儿童急性T淋巴细胞白血病(SIL-TAL1^(+)T-ALL)的临床和预后特征。方法:回顾性分析2010年1月至2018年12月我院儿科收治的110例初诊T-ALL患儿的临床资料,比较SIL-TAL1^(+)组和SIL-TAL1-组的临床特征、治疗反应和预后情况。结果:110例T-ALL患儿中,SIL-TAL1^(+)组有25例(22.7%),SIL-TAL1-组有85例(77.3%)。SIL-TAL1^(+)组的初诊白细胞计数明显高于SIL-TAL1-组(P<0.05),两组间的其他临床特征及治疗反应均无明显差异。SIL-TAL1^(+)组和SIL-TAL1-组的5年总生存(OS)率分别为80.0%和75.5%,5年无病生存(DFS)率分别为76.0%和72.9%,两组间OS率及DFS率比较差异均无统计学意义(P>0.05)。在初诊年龄<10岁的患儿中,SIL-TAL1^(+)组与SIL-TAL1-组的5年OS率分别为100%与75.1%,两组间的差异具有统计学意义(P<0.05)。结论:儿童SIL-TAL1^(+)T-ALL初诊时白细胞水平更高,临床疗效与SIL-TAL1-无显著差异。但在初诊年龄<10岁的T-ALL患儿中,SIL-TAL1^(+)组的长期生存率明显更优。
Objective:To explore the clinical characteristics and prognosis of children with SIL-TAL1-positive T-cell acute lymphoblastic leukemia(SIL-TAL1^(+)T-ALL).Methods:The clinical data of 110 children with newly diagnosed T-ALL admitted to the pediatric department of our hospital from January 2010 to December 2018 were reviewed to compare the clinical characteristics,treatment response and prognosis between SIL-TAL1^(+)group and SIL-TAL1-group.Results:Among the 110 children with T-ALL,25 cases(22.7%)were in the SIL-TAL1^(+)group and 85 cases(77.3%)in the SIL-TAL1-group.The white blood cell(WBC)count in the SIL-TAL1^(+)group was significantly higher than that in the SIL-TAL1-group(P<0.05),while the other clinical characteristics and treatment response were not significantly different between the two groups.The 5-year overall survival(OS)rates of SIL-TAL1^(+)group and SIL-TAL1-group were 80.0%and 75.5%,and 5-year disease-free survival(DFS)rates were 76.0%and 72.9%,respectively.There were no significant differences in OS rate and DFS rate between the two groups(P>0.05).In children aged<10 years,the 5-year OS rate of SIL-TAL1^(+)group and SIL-TAL1-group was 100%and 75.1%,respectively,and the difference between the two groups was statistically significant(P<0.05).Conclusion:Although the WBC level is significantly higher in children with SIL-TAL1^(+)T-ALL than that in those with SIL-TAL1-T-ALL,the treatment efficacy is similar between the two groups.In children aged<10 years,the long-term survival rate is superior in the SIL-TAL1^(+)group.
作者
薛玉娟
王毓
张乐萍
陆爱东
贾月萍
曾慧敏
XUE Yu-Juan;WANG Yu;ZHANG Le-Ping;LU Ai-Dong;JIA Yue-Ping;ZENG Hui-Min(Department of Pediatrics,Peking University People′s Hospital,Beijing 100044,China)
出处
《中国实验血液学杂志》
北大核心
2025年第5期1262-1268,共7页
Journal of Experimental Hematology
基金
国家自然科学基金(8200010526)。
